NFA
FLNA

Northwest Financial Advisors’s Filana Therapeutics FLNA Stock Holding History

Northwest Financial Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,089
Closed -$32K – 455
2024
Q3 		$32K Buy
+1,089
New +$25.1K 0.03% 275
2024
Q1 		– Sell
-1,089
Closed -$24.5K – 433
2023
Q4 		$24.5K Buy
+1,089
New +$23K 0.02% 282

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Northwest Financial Advisors's FLNA Position: Q4 2024 in Review

Northwest Financial Advisors sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 1,089 shares — an estimated $32K sold.

Northwest Financial Advisors first reported a position in FLNA in Q4 2023 and held it in 2 quarters. The position peaked at $32K in Q3 2024. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • Northwest Financial Advisors reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Northwest Financial Advisors sold 1,089 Filana Therapeutics shares in Q4 2024, an estimated $32K.
  • Northwest Financial Advisors first reported a position in Filana Therapeutics in Q4 2023 and held it in 2 quarters.
  • Northwest Financial Advisors's Filana Therapeutics position peaked at $32K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Northwest Financial Advisors's 13F filing for Q4 2024, filed 22 Jan 2025.